STERIS (STE) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $2.59
- EPS estimate
- $2.49
- EPS surprise
- +3.82%
- Revenue surprise
- +0.34%
- Revenue
- $1.5B
- Revenue estimate
- $1.5B
- Reported
- Aug 5, 2026
STERIS reported fiscal Q1 2027 results on August 5, 2026. Earnings per share came in at $2.59, ahead of the $2.49 estimate by 3.82%. Revenue was $1.5 billion, 0.34% above the consensus, which also rounds to $1.5 billion. Compared with fiscal Q1 2026, EPS rose about 11% from $2.34 and revenue rose about 7% from $1.4 billion.
Annual EPS rose from $8.21 in fiscal 2023 to $8.66 in 2024, $9.34 in 2025 and $10.17 in 2026. Q4 has been the largest quarter of each of those fiscal years, and Q4 2026 set the table's highs at $2.83 per share and $1.6 billion in revenue. The lowest EPS shown was $1.90 in Q1 2023. Quarterly revenue has moved up from $1.2 billion to $1.5 billion to $1.6 billion. Over the last 20 quarters, STERIS beat the EPS estimate 15 times and missed five. The largest was Q3 2023, at 7.90% below, and Q3 and Q4 2026 were narrow misses.
STERIS reported fiscal Q2 between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether year-over-year growth continues into fiscal 2027.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 5, 2026 | $2.49 | $2.59 | +3.82% | $1.5B | SEC |
| Q4 2026 | May 11, 2026 | $2.85 | $2.83 | −0.65% | $1.6B | SEC |
| Q3 2026 | Feb 4, 2026 | $2.53 | $2.53 | −0.10% | $1.5B | SEC |
| Q2 2026 | Nov 5, 2025 | $2.35 | $2.47 | +5.05% | $1.5B | SEC |
| Q1 2026 | Aug 6, 2025 | $2.26 | $2.34 | +3.37% | $1.4B | SEC |
| Q4 2025 | May 14, 2025 | $2.60 | $2.74 | +5.44% | $1.5B | SEC |
| Q3 2025 | Feb 5, 2025 | $2.32 | $2.32 | −0.06% | $1.4B | SEC |
| Q2 2025 | Nov 6, 2024 | $2.12 | $2.14 | +0.81% | $1.3B | SEC |
| Q1 2025 | Aug 6, 2024 | $1.98 | $2.14 | +8.24% | $1.3B | SEC |
| Q4 2024 | May 8, 2024 | $2.35 | $2.41 | +2.55% | $1.4B | SEC |
| Q3 2024 | Feb 7, 2024 | $2.17 | $2.22 | +2.37% | $1.4B | SEC |
| Q2 2024 | Nov 7, 2023 | $2.00 | $2.03 | +1.33% | $1.3B | SEC |
| Q1 2024 | Aug 1, 2023 | $1.86 | $2.00 | +7.53% | $1.3B | SEC |
| Q4 2023 | May 10, 2023 | $2.15 | $2.30 | +7.06% | $1.4B | SEC |
| Q3 2023 | Feb 8, 2023 | $2.19 | $2.02 | −7.90% | $1.2B | SEC |
| Q2 2023 | Nov 9, 2022 | $1.98 | $1.99 | +0.34% | $1.2B | SEC |
| Q1 2023 | Aug 2, 2022 | $1.92 | $1.90 | −0.78% | $1.2B | SEC |
| Q4 2022 | May 12, 2022 | $2.02 | $2.04 | +0.89% | $1.2B | SEC |
| Q3 2022 | Feb 8, 2022 | $1.96 | $2.12 | +8.05% | $1.2B | SEC |
| Q2 2022 | Nov 2, 2021 | $1.82 | $1.99 | +9.34% | $1.2B | SEC |
Quarterly revenue
Frequently asked questions
When did STERIS (STE) last report earnings?
STERIS last reported on Aug 5, 2026, covering fiscal Q1 2027.
Did STE beat earnings estimates?
Yes. STERIS reported EPS of $2.59 for Q1 2027 against a $2.49 estimate — a 3.82% beat.
How much revenue did STE report last quarter?
STERIS reported $1.5B in revenue for Q1 2027, against a consensus estimate of $1.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.